RxDoctor Payments Data

Roy Bankhead, MD

Urology · Oklahoma City, OKNPI 1477594513

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,482 of the $10,709 with a category attached, or 60.5%. 44 manufacturers reported payments, led by Medtronic at 46.4% of the total. Reporting peaked in 2023 at $5,154 and has fallen 83.2% since, to $867 in 2025.

$10,709in general payments, 2019–2025

Across 235 payments — averaging $45.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Procept Biorobotics Corporation$1K
  • Astellas Pharma US Inc$761
  • Healthtronics Stone Solutions, LLC$523
  • Teleflex LLC$409
  • Antares Pharma, Inc.$276
  • plus $3K from 38 others

What the payments were for

  • Travel & lodging$6126%
  • Food & beverage$6,48261%
  • Education$3023%
  • Other$3,31331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,709 in reported general payments places this provider in the 80th percentile of 145 urology providers in Oklahoma.

See all urology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$280,758
Medicare patients
684
Services billed
65,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron196$160,018
GemtesaVibegron57$49,297
Tamsulosin Hcl1,167$25,295
Alfuzosin Hcl ErAlfuzosin Hcl427$10,794
Solifenacin Succinate30$5,541
Tolterodine Tartrate ErTolterodine Tartrate50$5,147
Finasteride307$4,689
Potassium Citrate ErPotassium Citrate34$4,067
Trimethoprim79$3,554
Silodosin37$3,276
Tolterodine Tartrate45$3,163
Oxybutynin Chloride154$2,549
Dutasteride58$2,169
Oxybutynin Chloride ErOxybutynin Chloride75$1,630
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst93$1,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$761$160,018196 claims
Sumitomo Pharma America, Inc.Gemtesa$150$49,29757 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 145 urology providers in Oklahoma.

Other urology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →